It might be advisable to identify the BCR-ABL transcript type in CML patients at diagnosis, using an empirically verified method, in order to link the detected transcript with the clinical findings, possible resistance to treatment, and appropriate monitoring methods. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.